-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer ranks first among female malignant tumors.
On October 14, 2021, the international journal Cancer Cell published an online research titled "Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple negative breast cancer" from a Chinese scholar in the form of a Research Article.
Figure 1 Project research plan
By comparing the differences in the composition of tumors and peripheral blood immune cells of different responders in the combination therapy group, the researchers found that the tumor microenvironment of the responding patients was enriched in two groups of T cells with high expression of CXCL13 (CD8-CXCL13 and CD4-CXCL13).
Figure 2 Dynamic changes of T cell subsets under different treatment options
In addition, the researchers found that the tumor microenvironment of the responding patients was enriched in two groups of pro-inflammatory macrophages with high expression of CXCL9 and CXCL10, and there was a significant positive correlation between these two groups of pro-inflammatory macrophages and CXCL13+ T cells (Figure 3)
Figure 3 Tumor microenvironment and characteristics of myeloid cells in peripheral blood of TNBC patients
The tumor microenvironment is a complex ecosystem, in which innate immune and adaptive immune cells, stromal cells, cancer cells and their interactions constitute a fine regulatory network that together determine the occurrence and development of cancer
Figure 4 Dynamic changes of B cells and DC subgroups and their association with CXCL13+ T cells
The first author of the paper, Dr.
It is reported that this study is the largest single-cell omics study on TNBC tumor-related immune cells in the world so far.
Professor Liu Zhihua from Cancer Hospital of Chinese Academy of Medical Sciences, Professor Zhang Zemin from Peking University Biomedical Frontier Innovation Center (BIOPIC), Professor Ma Fei and Professor Xu Binghe from Cancer Hospital of Chinese Academy of Medical Sciences are the co-corresponding authors of the paper
